Ibsinorm

Ibsinorm Uses, Dosage, Side Effects, Food Interaction and all others data.

Ibsinorm is a serotonin type-4 (5HT4) receptor partial agonist. Ibsinorm binds with high affinity at human 5HT4 receptors, present on caudate membranes, whereas it has no appreciable affinity for human recombinant 5HT3 receptors or human recombinant dopamine D2 receptors. In vitro and animal study has revealed that Ibsinorm can trigger the peristaltic reflex via 5HT4 receptor activation and thereby enhance basal motor activity and normalize impaired GI motility.

In general, it has been determined that tegaserod is an agonist of serotonin type-4 (5-HT(4)) receptors, an antagonist at 5-HT(2B) receptors, but is expected to possess minimal binding to 5-HT(1) receptors, and virtually no affinity for 5-HT(3) or dopamine receptors .

In clinical trials with tegaserod, centrally analyzed ECGs were recorded in 4,605 male and female patients receiving tegaserod 6 mg twice daily or placebo for IBS-C and other related motility disorders . No subject receiving the agent had an absolute QTcF above 480 ms . An increase in QTcF of 30 to 60 ms was observed in 7% of patients receiving tegaserod and 8% receiving placebo . An increase in QTcF of greater than 60 ms was observed in 0.3% and 0.2% of subjects, respectively . The effects of tegaserod on the QTcF interval were ultimately not considered to be clinically meaningful .

Furthermore, it was determined that there is a potential for tegaserod and its main metabolite (the M29 metabolite) to increase platelet aggregation in vitro . In one in vitro study, at concentrations up to 10-times the maximum plasma concentration (Cmax) at the recommended dose, tegaserod significantly increased platelet aggregation in a concentration-dependent manner up to 74% (range 11% to 74%) compared to a control vehicle (with potentiation by various agonists) . In another in vitro study, the M29 metabolite, at concentrations up to 0.6-times the Cmax of M29 also showed a 5% to 16% increase in platelet aggregation compared to the control vehicle . The clinical implications of these in vitro platelet aggregation results remain unclear .

Trade Name Ibsinorm
Availability Prescription only
Generic Tegaserod
Tegaserod Other Names Tégasérod, Tegaserod, Tegaserodum
Related Drugs dicyclomine, Bentyl, hyoscyamine, Amitiza, Metamucil, Lotronex
Type Tablet
Formula C16H23N5O
Weight Average: 301.394
Monoisotopic: 301.190260381
Protein binding

The protein binding recorded for tegaserod is about 98% .

Groups Approved, Investigational, Withdrawn
Therapeutic Class Drugs for Irritable Bowel Syndrome
Manufacturer Ranbaxy Laboratories (sun Pharma), Sun Pharma
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Ibsinorm
Ibsinorm

Uses

Ibsinorm is used for the symptomatic treatment of irritable bowel syndrome with constipation (IBS-C) in patients whose main symptoms are constipation and abdominal pain or discomfort. The maximum duration of treatment is 12 weeks and treatment should be discontinued if there has been no response after 4 weeks.

Ibsinorm is also used to associated treatment for these conditions: Constipation-predominant Irritable Bowel Syndrome (IBS-C)

How Ibsinorm works

Irritable bowel syndrome (IBS) is a complex functional disorder comprised of various abnormal and discomforting effects on the gastrointestinal tract and bowel function . Although the cause of IBS has yet to be formally elucidated, patient experience has demonstrated that the disorder is typically associated with abdominal pain, abdominal distension, cramping or bloating, variations in urgency for bowel movements, feelings of incomplete evacuation, gastroesophageal reflux, and various other effects . In particular, IBS that features constipation as a predominant effect is categorized as constipation-predominant IBS, or IBS-C .

Concurrently, 5-Hydroxytryptamine (5-HT, or serotonin) has demonstrated the ability to elicit significant regulatory actions on gastrointestinal motility . Specifically, it has been shown that the activation of 5-HT(4) receptors located on motor neurons and interneurons in the gastrointestinal wall can cause the release of acetylcholine, substance P, and calcitonin gene-related peptide that can all facilitate the propulsion of material through the gut . Moreover, when 5-HT(4) receptors located in smooth muscle cells are also activated, activities that may alleviate symptoms of IBS-C like esophageal relaxation and the inhibition of human colonic circular muscle contraction can also occur . Additionally, activating 5-HT(4) on enteric neurons and enterocytes also cause natural fluid secretion in the gut - an action which also strongly assists in promoting the movement of content along the gastrointestinal tract .

Alternatively, it has also been observed that 5-HT may participate in generating visceral hyperalgesia in IBS, an observation supported in part by the finding of increased amounts of 5-HT and its metabolites in the plasma of patients experiencing IBS It has therefore also been proposed that antagonism of 5-HT(2B) receptors can lead to inhibition of both 5-HT mediated gastrointestinal motility and visceral hypersensitivity .

Subsequently, because tegaserod is considered to be an agonist of the 5-HT(4) receptor and an antagonist of the 5-HT(2B) receptor at clinically relevant levels, it is believed that tegaserod may elicit its mechanism of action by facilitating activities associated with the activation and antagonism of the 5-HT(4) and 5-HT(2B) receptors, like stimulating peristaltic gastrointestinal reflexes and intestinal secretion, inhibiting visceral sensitivity, enhancing basal motor activity, and normalizing impaired motility throughout the gastrointestinal tract, among other actions .

Dosage

Ibsinorm dosage

General recommended dosage for adult: Ibsinorm 6 mg twice daily taken orally with a glass of water 30 minutes before meal. The maximum duration of treatment is 12 weeks and treatment should be discontinued after 4 weeks if no response has occurred.

Use in elderly: Dose adjustment is not necessary when administering Ibsinorm to patients over 65 years old.

Use in children: There is no clinical trial in document to safety and efficacy of tegaserod in children. Therefore, it is not recommended for use in children.

Patient should be advised to take Ibsinorm (6 mg twice daily) 30 minutes before meal.

Patient should also be made aware of the possible occurrence of diarrhea during therapy. In most cases, the diarrhea occurred early, is transient, is most often observed as a single episode during the 12 week treatment period, and resolved with continued therapy.

Patients should be instructed to consult their physician if they experience new or worsening abdominal pain not typical of their IBS symptoms.

Side Effects

Abdominal pain, diarrhea, nausea, flatulence, headache, fatigue, back pain etc.

Toxicity

Single oral doses of 120 mg (which is 20 times the recommended dose) of tegaserod were administered to three healthy subjects in one study . All three subjects developed diarrhea and headache. Two of these subjects also reported intermittent abdominal pain and one developed orthostatic hypotension . In 28 healthy subjects exposed to 90 to 180 mg per day of tegaserod (which is 7.5 to 15 times the recommended daily dosage) for several days, adverse reactions were diarrhea (100%), headache (57%), abdominal pain (18%), flatulence (18%), nausea (7%), and vomiting (7%) .

Although available data from case reports with tegaserod use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, animal studies involving maternal dietary administration of tegaserod with doses 45 to 71 times the recommended dose demonstrated decreased body weight, delays in developmental landmarks, and decreased survival in rat pups . Caution and careful consideration of risks versus benefits are recommended before administering tegaserod to a pregnant woman.

Despite there being little if any data available regarding the presence of tegaserod in human milk, the effects on the breastfed infant, or the effects on milk production, tegaserod and its metabolites are present in rat milk and the milk to plasma concentration ratio is very high in rats . Subsequently, because of the potential for serious reactions in the breastfed infant, including tumorigenicity, breastfeeding is not recommended during treatment with tegaserod .

The safety and effectiveness of tegaserod in pediatric patients has not yet been established .

Ibsinorm is not indicated in patients that are aged 65 years or older .

Ibsinorm was not carcinogenic in rats given oral dietary doses up to 180 mg/kg/day (approximately 93 to 111 times the recommended dose based on AUC) for 110 to 124 weeks . In mice, dietary administration of tegaserod for 104 weeks produced mucosal hyperplasia and adenocarcinoma of the small intestine at 600 mg/kg/day (approximately 83 to 110 times the recommended dose based on AUC) . There was no evidence of carcinogenicity at lower doses (3 to 35 times the recommended dose based on AUC) . Ibsinorm was not genotoxic in the in vitro Chinese hamster lung fibroblast (CHL/V79) cell chromosomal aberration and forward mutation test, the in vitro rat hepatocyte unscheduled DNA synthesis (UDS) test or the in vivo mouse micronucleus test . The results of the Ames test for mutagenicity were equivocal. Ibsinorm at oral (dietary) doses up to 240 mg/kg/day (approximately 57 times the recommended dose based on AUC) in male rats and 150 mg/kg/day (approximately 42 times the recommended dose based on AUC) in female rats was found to have no effect on fertility and reproductive performance .

Inhibition of the hERG (human Ether-a-go-go-Related Gene) channel was evident only in the micromolar concentration range with an IC50 of 13 micromolar (approximately 1300 times the Cmax in humans at the recommended dose) . In in vitro studies, tegaserod had no effects on impulse conduction in isolated guinea pig papillary muscle at up to 100 times the Cmax in humans, Langendorff-perfused isolated rabbit heart (QT interval) at up to 1000 times the Cmax in humans, or human atrial myocytes at multiples up to 10 times the Cmax in humans . The major metabolite, M29, had no effect on QT in the Langendorff-perfused isolated rabbit heart at multiples up to 323 times the Cmax in humans .

In anesthetized and conscious dogs, tegaserod at doses up to 92 to 134 times the recommended dose based on Cmax did not alter heart rate, QRS interval duration, QTc or other ECG parameters . In chronic toxicology studies in rats and dogs, there were no treatment-related changes in cardiac morphology after tegaserod administration at doses up to 660 times the recommended dose based on AUC .

Although tegaserod is expected to bind to 5-HT2B receptors in humans at the recommended dose, there does not appear to be any potential for heart valve injury based on functional evidence of 5-HT2B receptor antagonism .

Studies with isolated coronary and mesenteric blood vessels from non-human primates and humans showed no vasoconstrictor effect at concentrations approximately 100 times the human Cmax . Ibsinorm exhibited antagonism of 5-HT-mediated vasoconstriction via 5-HT1B receptors . In rat thoracic aortic rings that were pre-constricted with phenylephrine or norepinephrine, tegaserod produced vasorelaxation, with IC50 values 6 and 64 times the Cmax plasma concentrations in humans, respectively . No effects were observed in the basal tone of aortic rings at concentrations up to 1000 times the human Cmax .

In studies with an anesthetized rat model for measuring macro- and micro-circulation of the colon, intraduodenal dosing with tegaserod (approximately 7 times the recommended dose based on Cmax) produced no clinically relevant effect on blood pressure, heart rate, or vascular conductance .

Precaution

Diarrhea was reported in some of the patients receiving Ibsinorm in the Phase III clinical studies. Caution is required in patients in whom increased diarrhea could have negative effects. Patients who are currently experiencing or frequently experience diarrhea should not initiate therapy with Ibsinorm.

Interaction

No clinically relevant drug-drug interactions have been observed with dextromethorphan, theophylline, digoxin, oral contraceptives, and warfarin.

Food Interaction

  • Take before a meal. To increase absorption, take 30 minutes before a meal.

[Moderate] ADJUST DOSING INTERVAL: Food reduces the bioavailability of tegaserod by 40 to 65% and the maximum plasma concentration (Cmax) by 20 to 40%.

MANAGEMENT: Ibsinorm should be taken before meals.

Volume of Distribution

Although tegaserod is not approved for intravenous administration, data regarding the mean volume of distribution of tegaserod at steady-state is recorded as 368 ± 223 L following research of tegaserod administered intravenously .

Elimination Route

The absolute bioavailability of tegaserod is approximately 10% when administered to fasting subjects. The median time of peak tegaserod plasma concentration (Tmax) is approximately one hour (range 0.7 to 2 hours) .

Nevertheless, when tegaserod was given to individuals thirty minutes before a meal of high-fat and high-calorie content (about 150 calories from protein, 250 calories from carbohydrates, and 500 calories from fat), the AUC was reduced by 40% to 65%, the Cmax was reduced by approximately 20% to 40%, and the median Tmax was 0.7 hours . Additionally, plasma concentrations were similar when tegaserod was administered within thirty minutes before a meal or even two and a half hours after a meal .

Half Life

The mean terminal elimination half-life documented for tegaserod ranges from 4.6 to 8.1 hours following oral administration .

Clearance

Although tegaserod is not approved for intravenous administration, data regarding the mean plasma clearance of tegaserod is documented as 77 ± 15 L/h following research of tegaserod administered intravenously .

Elimination Route

Approximately two-thirds of an orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine as metabolites .

Pregnancy & Breastfeeding use

Pregnancy: In view of limited experience in human, use of Ibsinorm during pregnancy is not recommended.

Nursing mothers: Ibsinorm should not be prescribed to nursing mothers.

Contraindication

Ibsinorm is not recommended in patients with severe renal or hepatic impairment. It is also contraindicated in patients with hypersensitivity to tegaserod or any excipient of this formulation.

Special Warning

Renal impairment: No dosage adjustment is required in patients with mild to moderate renal impairment. Ibsinorm is not recommended in patients with severe renal impairment.

Hepatic impairment: No dosage adjustment is required in patients with mild to moderate hepatic impairment, however, caution is recommended when using Ibsinorm in this patient population. It has not been studied in patients with severe hepatic impairment, and therefore, it is not recommended in this group.

Acute Overdose

Signs and symptoms of overdosage may include diarrhoea, headache, abdominal pain and orthostatic hypotension. As in any case of over dose, general supportive measures should be utilized.

Storage Condition

Store at a cool and dry place, protected from light and moisture.

Innovators Monograph

You find simplified version here Ibsinorm

Ibsinorm contains Tegaserod see full prescribing information from innovator Ibsinorm Monograph, Ibsinorm MSDS, Ibsinorm FDA label

FAQ

What is Ibsinorm used for?

Ibsinorm is used to treat adult women less than 65 years of age who have irritable bowel syndrome (IBS) with constipation as their main problem.

how safe is Ibsinorm?

Ibsinorm appears to be well tolerated in the treatment of patients with constipation-predominant irritable bowel syndrome.

What are the common side effects of Ibsinorm?

Common side effects of Ibsinorm include:

  • headache,
  • dizziness,
  • migraine,
  • back pain,
  • joint pain,
  • stomach or abdominal pain,
  • nausea,
  • vomiting,
  • gas,
  • bloating,
  • diarrhea,
  • leg pain, and
  • fatigue

Is Ibsinorm safe during pregnancy?

Ibsinorm is only recommended for use during pregnancy when the benefit outweighs the risk.Ibsinorm has been assigned to pregnancy category B by the FDA. Animal studies have revealed no evidence of fetal harm. There are no controlled data in human pregnancy.

Is Ibsinorm safe during breasfeeding?

It is unknown if this drug passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

When is the best time to take Ibsinorm?

Food can decrease the levels of btrand in your body. Take Ibsinorm on an empty stomach at least 30 minutes before or 2 hours after a meal. This will make it easier for your body to absorb the medicin

Can I take Ibsinorm long time?

Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.Take this medicine only as directed by your doctor.

How quickly does Ibsinorm work?

It may take up to 2 weeks of using this medicine before your symptoms improve. For best results, keep using the medication as directed.

What should I avoid while taking Ibsinorm?

Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using Ibsinorm.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine.
Overdose symptoms may include diarrhea, stomach pain, nausea, and vomiting.

What happens if I miss a dose?

If you miss a dose or forget to take your medicine, wait until it is time for your next dose and skip the missed dose. Do not take extra medicine to make up the missed dose.

How should I take Ibsinorm?

Do not take it in larger amounts or for longer than recommended. Take this medication with a full glass of water.Take Ibsinorm on an empty stomach. Ibsinorm is usually taken twice daily.

How does Ibsinormwork?

It works by improving muscle movement and increasing production of fluid in the bowels.

http://classyfire.wishartlab.com/tax_nodes/C0000000
http://classyfire.wishartlab.com/tax_nodes/C0000002
http://classyfire.wishartlab.com/tax_nodes/C0000211
http://classyfire.wishartlab.com/tax_nodes/C0002497
http://classyfire.wishartlab.com/tax_nodes/C0002497
http://classyfire.wishartlab.com/tax_nodes/C0000138
http://classyfire.wishartlab.com/tax_nodes/C0000128
http://classyfire.wishartlab.com/tax_nodes/C0002257
http://classyfire.wishartlab.com/tax_nodes/C0004144
http://classyfire.wishartlab.com/tax_nodes/C0000375
http://classyfire.wishartlab.com/tax_nodes/C0003152
http://classyfire.wishartlab.com/tax_nodes/C0004139
http://classyfire.wishartlab.com/tax_nodes/C0004557
http://classyfire.wishartlab.com/tax_nodes/C0000117
http://classyfire.wishartlab.com/tax_nodes/C0004150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51043
http://www.genome.jp/dbget-bin/www_bget?drug:D06056
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5362436
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506519
https://www.chemspider.com/Chemical-Structure.10609889.html
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=79022
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=139778
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=51043
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL76370
https://zinc.docking.org/substances/ZINC000001545565
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001526
http://www.pharmgkb.org/drug/PA130413154
http://www.rxlist.com/cgi/generic3/zelnorm.htm
https://www.drugs.com/cdi/tegaserod.html
https://en.wikipedia.org/wiki/Tegaserod
*** Taking medicines without doctor's advice can cause long-term problems.
Share